^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G)

    i
    Other names: TN-TC11G, THC/CBD
    Associations

    News

    Trials
    Company:
    Tilray
    Drug class:
    Cannabinoid receptor modulator
    Related drugs:
    Associations

    News

    Trials
    10d
    GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=33, Completed, Grupo Español de Investigación en Neurooncología | Active, not recruiting --> Completed | Trial primary completion date: Mar 2025 --> Nov 2025
    Trial completion • Trial primary completion date
    |
    temozolomide • delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G)
    over1year
    GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Grupo Español de Investigación en Neurooncología | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    temozolomide • delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G)
    over2years
    GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Grupo Español de Investigación en Neurooncología | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MDK (Midkine)
    |
    temozolomide • delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G)
    almost3years
    GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Grupo Español de Investigación en Neurooncología | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    MDK (Midkine)
    |
    temozolomide • delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G)
    over3years
    GEINOCANN: TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Grupo Español de Investigación en Neurooncología | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    MDK (Midkine)
    |
    temozolomide • delta-9-tetrahydrocannabinol/cannabidiol (TN-TC11G)